Prevention of anthracycline-induced cardiotoxicity as a new potential indication for statins?

Czech version

Authors: Beata Mladosievičová
Authors‘ workplace: Oddelenie klinickej patofyziológie, Ústav patologickej fyziológie LF UK, Bratislava
Published in: AtheroRev 2026; 11(1): 50-55
Category: Reviews

Overview

Cardiovascular diseases induced by anthracycline cytostatics are among the most serious long-term/late complications of cancer treatment. It is not uncommon that, in terms of potential cardiotoxicity, it is necessary to constantly reveal new options for cardioprotection based on recent findings regarding the pathogenesis of anthracycline cardiotoxicity, especially in high-risk patients. Given their pleiotropic effects, statins appear to have a much broader role in cardio-oncology than originally anticipated. The stratification of cardiovascular risk in cancer patients treated with anthracycline cytostatics and close cooperation between oncologists, cardiologists, and specialists in cardiometabolic diseases are gaining new importance in clarifying the role of statins in cardioprotection.

Keywords:

cardioprotection – anthracycline-induced cardiotoxicity – cancer patients

Sources

1. Sturgeon KM, Deng L, Bluethmann SM et al. A populationbased study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019; 40(48): 3889–3897. Dostupné z DOI: <http://dx.doi.org/10.1093/ eurheartj/ehz766>.

2. Florido R, Daya NR, Ndumele CE et al. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol 2022; 80(1): 22–32. Dostupné z DOI: <http:// dx.doi.org/10.1016/j.jacc.2022.04.042>.

3. Grilz E, Posch F, Nopp S et al. Relative risk of arterial and venous thromboembolism in persons with cancer vs persons without cancera nationwide analysis. Eur Heart J 2021; 42(23): 2299–2307. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab171>.

4. Mladosievičová B (ed). Kardioonkologie. 2. ed. Grada Publishing: Praha 2014. ISBN 978–80–247–4838–2.

5. Ball S, Ghosh RK, Wongsaengsakiol S et al. Cardiovascular toxicities of immune checkpoint inhibitors. J Am Coll Card 2019; 74(13): 1714–1727. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2019.07.079>.

6. Patnaik JL, Byers T, DiGuiseppi C et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011; 13(3): R 64. Dostupné z DOI: <http://dx.doi.org/10.1186/bcr2901>.

7. Herrmann J. From trends to transformation: where cardiooncology is to make a difference. Eur Heart J 2019; 40(48): 3898–3900. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz781>.

8. Armenian SH, Hudson MM, Mulder RL et al. [International Late Effects of Childhood Cancer Guideline Harmonization Group]. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015; 16(3): e123–36. Dostupné z DOI: <http://dx.doi.org/10.1016/S1470–2045(14)70409–7>.

9. Armenian SH, Lacchetti C, Barac A et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35(8): 893 –⁠ 911. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2016.70.5400>.

10. Lyon AR, LópezFernández T, Couch LS et al. [ESC Scientific Document Group]. 2022 ESC Guidelines on cardiooncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International CardioOncology Society (ICOS). Eur Heart J 2022; 43(41): 4229–4361. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehac244>.

11. Curigliano G, Lenihan D, Fradley M et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31(2): 171–190. Dostupné z DOI: <http://dx.doi.org/10.1016/j.annonc.2019.10.023>.

12. Mach F, Koskinas KC, Roeters van Lennep JE et al. [ESC/EAS Scientific Document Group]. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025; 46(42): 4359 –⁠ 4378. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaf190>. Erratum in: Eur Heart J 2025: ehaf1036. Dostupné z DOI: <http://dx.doi. org/10.1093/eurheartj/ehaf1036>.

13. Camilli M, Cipolla CM, Dent S et al. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology StateoftheArt Review. JACC CardioOncol 2024; 6(5): 655–677. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaccao.2024.07.016>.

14. Reinbolt RE, Patel R, Pan X et al. Risk factors for anthracyclineassociated cardiotoxicity. Support Care Cancer 2016; 24(5): 2173–2180. Dostupné z DOI: <http://dx.doi.org/10.1007/s00520–015–3008y>.

15. AlOtaibi TK, Weitzman B, Tahir UA et al. Genetics of AnthracyclineAssociated Cardiotoxicity. Front Cardiovasc Med 2022; 9 : 867873. Dostupné z DOI: <http://dx.doi.org/10.3389/fcvm.2022.867873>.

16. Faktorová X, Luknár M, Zelinková Z et al. Závažné zlyhávanie srdca a arytmia po protinádorovej liečbe podávanej v detstve. [Advanced heart failure and cardiac arrhythmia in a young adult survivor of childhood cancer]. Vnitr Lek 2022; 68(E1): 22–26.

17. Spadafora L, Di Muro FM, Intonti C et al. Lifestyle and Pharmacological Interventions to Prevent AnthracyclineRelated Cardiotoxicity in Cancer Patients. J Cardiovasc Dev Dis 2025; 12(6): 212. Dostupné z DOI: <http:// dx.doi.org/10.3390/jcdd12060212>.

18. Rečková M. Kardiotoxicita systémovej onkologickej liečby z pohľadu onkológa. Kardiol Prax 2022; 20(4): 207–211.

19. Henninger C, Fritz G. Statins in anthracyclineinduced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death Dis 2017; 8(1): e2564. Dostupné z DOI: <http://dx.doi.org/10.1038/cddis.2016.418>.

20. Clayton ZS, Hutton DA, Mahoney SA et al. Anthracycline chemotherapymediated vascular dysfunction as a model of accelerated vascular aging. Aging Cancer 2021; 2(1–2): 45–69. Dostupné z DOI: <http://dx.doi. org/10.1002/aac2.12033>.

21. Neilan TG, Quinaglia T, Onoue T et al. Atorvastatin for anthracyclineassociated cardiac dysfunction: the STOPCA randomized clinical trial. JAMA 2023; 330(6): 528–536. Dostupné z DOI: <http://dx.doi. org/10.1001/jama.2023.11887>.

22. Nabati M, Janbabai G, Esmailian J et al. Effect of rosuvastatin in preventing chemotherapyinduced cardiotoxicity in women with breast cancer: a randomized, singleblind, placebocontrolled trial. J Cardiovasc Pharmacol Ther 2019; 24(3): 233–241. Dostupné z DOI: <http://dx.doi. org/10.1177/1074248418821721>.

23. Hundley WG, D’Agostino R Jr, Crotts T et al. Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. NEJM Evid 2022; 1(9): 10.1056/evidoa2200097. Dostupné z DOI: <http://dx.doi.org/10.1056/ evidoa2200097>.

24. Thavendiranathan P, Houbois C, Marwick TH et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother 2023; 9(6): 515–525. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjcvp/pvad031>.

25. Acar Z, Kale A, Turgut M et al. Efficiency of atorvastatin in the protection of anthracyclineinduced cardiomyopathy. J Am Coll Cardiol 2011; 58(9): 988–989. Dostupné z DOI: <http://dx.doi.org/10.1016/j. jacc.2011.05.025>.

26. Agarwal S, Guha A, Krishan S et al. Statins for Primary Prevention of Anthracycline ChemotherapyRelated Cardiac Dysfunction: A Systematic Review and Metaanalysis of Randomized Controlled Trials. Am J Cardiol 2023; 206 : 63–66. Dostupné z DOI: <http://dx.doi.org/10.1016/j. amjcard.2023.08.123>.